Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects
John D. Davis(Providence College), Georges Weissgerber(Alcon (United States)), David Sudworth(Pfizer (United Kingdom)), Tracy Higgins(Pfizer (United Kingdom)), Gary Layton(University of Geneva), Frances Hackman(Pfizer (United Kingdom))
Cited by 28
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
|Journal of the American Academy of Dermatology|2020|396